, a Danaher company recognized for its contributions to genomics and molecular biology, has entered a research collaboration with Profluent Bio, a biotechnology company specializing in artificial intelligence–based protein engineering.){kind=link}
Integrated DNA Technologies (IDT), a Danaher company recognized for its contributions to genomics and molecular biology, has entered a research collaboration with Profluent Bio, a biotechnology company specializing in artificial intelligence–based protein engineering. The partnership seeks to develop and refine next-generation enzymes through the integration of machine learning–based design and experimental validation.
At IDT, we’ve built a strong enzyme engineering capability—innovating proprietary enzymes that have powered countless scientific breakthroughs. This collaboration with Profluent Bio represents a bold step forward in our strategic roadmap. By integrating Profluent’s AI-driven protein design with IDT’s enzymology and genomics expertise, we will unearth new possibilities across a broad range of critical applications, from epigenetics to cancer research and beyond.
Ajay Gannerkote, President of Integrated DNA Technologies
The initiative combines Profluent Bio’s generative AI platform with IDT’s established capabilities in enzymology, genomics, and large-scale synthesis. A key component of the collaboration is the application of Profluent’s foundational models, including the recently released ProGen3, which are trained on the Profluent Protein Atlas, a multibillion-sequence dataset designed to capture broad biological diversity and enable high-fidelity modeling of protein function. Previous applications of this AI framework include the development of OpenCRISPR-1™, regarded as the first gene-editing enzyme generated entirely through artificial intelligence.
Under the new agreement, IDT will assess and optimize AI-generated enzyme candidates within its existing enzyme development and manufacturing infrastructure. The company will conduct validation and scalability studies to determine the feasibility of integrating these designs into commercial product lines supporting genomics, synthetic biology, and gene-editing workflows.
Pairing Profluent’s AI with IDT’s world-class enzymology and manufacturing expertise is a powerful way to bring new capabilities to researchers and the industry. This partnership reflects our belief that AI-designed proteins can unlock step-changes in enzyme efficiency, precision, and manufacturability, without being constrained by what evolution has already tried.
Ali Madani, PhD, founder and CEO of Profluent Bio
As part of Danaher’s broader strategy to incorporate artificial intelligence into molecular design and biomanufacturing, this collaboration represents a significant extension of IDT’s research footprint in the San Francisco Bay Area. The site serves as a hub for innovation focused on the development of synthesis technologies and enzymatic tools relevant to oncology and genomic research.